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Introduction
Integrins are a family of heterodimeric cell adhesion receptors, 
which not only mediate cell adhesion to extracellular matrix 
proteins but also transmit signals that are vital for anchorage-
dependent cell survival, proliferation, and motility (Hynes, 2002). 
Thus, integrins play pivotal roles in physiological processes such 
as wound healing, immune responses, and hemostasis. Aberrant 
integrin signaling is also centrally involved in the development 
of human diseases such as thrombosis, cancer, and autoimmune 
diseases and is the target of many therapeutic agents (Hynes, 
2002; Shattil and Newman, 2004). Therefore, understanding the 
molecular events in the transduction of integrin signals is impor-
tant in our understanding of many biological processes and has 
the potential to reveal novel intervention for diseases.
Integrin signaling is bidirectional in that ligand binding 
function of integrins requires conformational change in the 
extracellular ligand binding domain induced by intracellular 
signals (inside-out signaling), and ligand binding transduces 
outside-in signals that mediate cellular responses (Hynes, 2002; 
Vinogradova et al., 2002; Ginsberg et al., 2005; Wegener et al., 
2007). An early functional outcome of integrin outside-in signaling 
is cell spreading, which is characterized by the formation of fi  lo-
podia and lamellipodia and represents the outward movement of 
cell membrane, polymerizing actin, and cytoskeletal complexes at 
the leading edge (Hall, 2005). Integrin signaling later induces cell 
retraction, which is the inward movement of the cell membrane and 
cytoskeletal complexes, often at the rear end of cells. Coordinated 
spreading and retraction allows cell migration and in blood plate-
lets facilitates stable platelet adhesion, thrombus formation, and 
consolidation. It has been shown that small GTP binding pro-
teins Rac and cdc42 are involved in signaling mechanisms of cell 
spreading and that RhoA-mediated signaling is important in cell 
retraction (Hall, 2005). However, it remains unclear how integrin 
signaling initiates and temporally regulates these two seemingly 
opposing cellular responses; this is a fundamental question in 
cell biology. In this study, we have discovered that calpain cleav-
age of β3 at Tyr
759 serves as a molecular switch that changes the 
outcome of the integrin outside-in signals from mediating cell 
spreading to promoting cell retraction. Furthermore, the switch 
from cell spreading to retraction is mediated by calpain cleavage 
of the c-Src binding site at the integrin C terminus, which relieves 
the c-Src–dependent inhibition of RhoA, and thus facilitates 
integrin-mediated, RhoA-dependent contractile signaling.
Results
A calpain cleavage–resistant 𝗃3 mutant
We have previously reported that the calcium-dependent prote-
ase calpain cleaves the cytoplasmic domain of the integrin β3 
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ntegrin-dependent cell spreading and retraction are 
required for cell adhesion, migration, and proliferation, 
and thus are important in thrombosis, wound repair, 
immunity, and cancer development. It remains unknown 
how integrin outside-in signaling induces and controls 
these two opposite processes. This study reveals that cal-
pain cleavage of integrin β3 at Tyr
759 switches the func-
tional outcome of integrin signaling from cell spreading to 
retraction. Expression of a calpain cleavage–resistant β3 
mutant in Chinese hamster ovary cells causes defective 
clot retraction and RhoA-mediated retraction signaling but 
enhances cell spreading. Conversely, a calpain-cleaved 
form of β3 fails to mediate cell spreading, but inhibition of 
the RhoA signaling pathway corrects this defect. Impor-
tantly, the calpain-cleaved β3 fails to bind c-Src, which is 
required for integrin-induced cell spreading, and this 
requirement of β3-associated c-Src results from its inhibi-
tion of RhoA-dependent contractile signals. Thus, calpain 
cleavage of β3 at Tyr
759 relieves c-Src–mediated RhoA 
inhibition, activating the RhoA pathway that conﬁ  nes cell 
spreading and causes cell retraction.
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subunit mainly at Y
759, thus removing the C-terminal RGT
762 
sequence (Du et al., 1995; Xi et al., 2003). Calpain cleavage of 
β3 is inhibited by tyrosine phosphorylation at Y
759 of the β3 
cytoplasmic domain (Xi et al., 2006). To understand the 
physiological role of calpain cleavage of β3, we developed a 
calpain-resistant mutant of β3 by replacing R
760 with a nega-
tively charged glutamic acid (R760E; Fig. 1 A). This mutation 
is intended to mimic the effect of phosphorylation at the adja-
cent Y
759 by inhibiting calpain cleavage without perturbing the 
functionally critical NITY motif. The R760E mutant was stably 
expressed in a CHO cell line (Gu et al., 1999) together with the 
wild-type (WT) integrin αIIb subunit. To determine whether the 
R760E mutant confers resistance to calpain-mediated proteoly-
sis, lysates from cells expressing WT integrin αIIbβ3 and the 
R760E mutant were incubated with or without purifi  ed μ-calpain 
and immunoblotted with Ab762, an antibody recognizing the 
intact β3 C-terminal TYRGT
762 sequence, or Ab759, an anti-
body that recognizes the β3 TNITY
759 sequence only when β3 is 
cleaved by calpain at Y
759 (Du et al., 1995; Xi et al., 2003). 
The specifi  cities of these antibodies have been previously char-
acterized in Du et al. (1995) and Xi et al. (2003). In particular, 
we have shown that the calpain cleavage–specifi  c antibody 
Ab759 only reacts with the β3 that is truncated at the C-terminal 
side of Y
759 and fails to recognize β3 that is not cleaved (WT) or 
truncated at different sites, and that Ab762 reacts only with WT 
β3 that is not cleaved and fails to react with β3 cleaved at Y
759 or 
other sites (Xi et al., 2003). MAb 15, recognizing the β3 extra-
cellular domain (which is not disturbed by calpain; Du et al., 
1995), serves as loading control (Fig. 1 B). WT β3 shows a 
large increase in reactivity with Ab759 after treatment with 
μ-calpain. This increase is mirrored by the loss of reactivity with 
Ab762, indicating loss of intact C terminus. In contrast, calpain-
treated R760E mutant β3 showed no decrease in Ab762 re-
action and dramatically diminished reactivity with Ab759. 
The relatively low reactivity of Ab762 with the R760E mutant 
compared with WT β3 is caused by R
760 to E mutation but is not 
Figure 1.  A calpain cleavage–resistant mutation of 𝗃3: R760E. (A) WT β3 cytoplasmic domain sequence and the R760E mutation. (B) Cells expressing 
WT and R760E mutant αIIbβ3 were solubilized, treated with or without puriﬁ  ed μ-calpain, and immunoblotted with anti-β3 C-terminal antibody Ab762, calpain 
cleavage–indicator antibody Ab759, and the anti-β3 extracellular domain antibody mAb 15. Note that although R760E showed lower reactivity with 
Ab762 because of mutation in the epitope (TYR
760GT), calpain caused minimal loss of Ab762 reactivity or gain of Ab759 reactivity, which indicates cal-
pain resistance. (C) Analysis of stable αIIbβ3 expression in cells expressing WT and R760E mutant integrins, using the monoclonal anti-αIIbβ3 antibody D57. 
(D) WT and R760E cells spreading on ﬁ  brinogen were permeabilized and stained with mAb 15 (green) and puriﬁ  ed Ab759 (red). Ab759 staining of 
R760E cells was reduced compared with WT β3. Bar, 10 μm. SWITCHING THE DIRECTION OF INTEGRIN SIGNALING • FLEVARIS ET AL. 555
caused by reduced R760E expression, as indicated by the reac-
tion with mAb 15. These results demonstrate that R760E muta-
tion is calpain cleavage resistant (Fig. 1 B). Levels of stable 
surface expression of the R760E mutant and WT αIIbβ3 were 
also analyzed by fl  ow cytometry to ensure comparable expres-
sion after repeated cell sorting with an anti-αIIbβ3 monoclonal 
antibody, D57 (Fig. 1 C). We showed previously that the β3 cyto-
plasmic domain is cleaved by endogenous calpain in platelets and 
integrin-expressing CHO cells adherent to fi  brinogen (Xi et al., 
2003). To test whether R760E is resistant to endogenous calpain 
during cell adhesion, CHO cells containing either WT cells or 
R760E mutant β3 were allowed to adhere and spread on immo-
bilized fi  brinogen and were subsequently immunolabeled with 
affi  nity-purifi  ed cleavage-specifi  c antibody Ab759 to detect 
integrin cleavage and with mAb 15 to mark β3. WT β3 was 
cleaved by calpain (Fig. 1 D). In contrast, the R760E mutant 
Figure 2.  Effects of cleavage-resistant 𝗃3 mutation, R760E, and calpain inhibition on clot retraction and 𝗃3 cleavage. (A) Fibronectin-depleted plasma 
mixed with WT or R760E cells was induced to coagulate with 2 U/ml thrombin at 37°C for the indicated times, and then photographed. (B) Quantiﬁ  cation 
of clot size at various time points in A. Error bars are the SD from three separate experiments. (C) Clots containing WT or R760E cells were ﬁ  xed at 1 h, 
cryosectioned, stained with puriﬁ  ed Ab759 (red) or mAb 15 (green), and observed by confocal microscopy. Note the reduced Ab759 staining of R760E 
cells. Bars, 10 μm. (D) Clot retraction by WT cells preincubated with either 5 μM of calpain inhibitor MDL 28170 or vehicle control. (E) Quantiﬁ  cation of 
clot sizes in D (mean ± SD). (F) Washed platelets from WT and μ-calpain knockout mice were incubated in an aggregometer with or without 0.1 U/ml 
thrombin for 7 min. β3 cleavage at Y
759, which was detected using cleavage-speciﬁ  c antibody Ab759, was enhanced in the WT compared with the calpain 
knockout. Ab8053 recognizes β3 extracellular domain and serves as a loading control.JCB • VOLUME 179 • NUMBER 3 • 2007  556
showed marked reduction in calpain cleavage (Fig. 1 D). Thus, 
the R760E mutation renders β3 resistant to cleavage by calpain 
in cells adherent to fi  brinogen.
The effects of calpain resistance on 
𝗃3-mediated clot retraction and 
cell spreading
Fibrin clot retraction, mediated by platelets and β3 integrin–
expressing cells, requires β3-dependent outside-in signaling and 
cell retraction (Chen et al., 1994; Law et al., 1996). To deter-
mine whether and how the calpain-resistant mutation of β3 af-
fects integrin signaling, we compared the ability of the WT 
β3- and R760E-expressing cells to mediate clot retraction (Fig. 2, 
A and B). Clot retraction mediated by R760E cells was sig-
nifi  cantly decreased (P < 0.001). Consistent with this result, 
calpain cleaved WT β3 at Y
759 during clot retraction, and this 
cleavage was impeded in the R760E mutant cells (Fig. 2 C). 
It was previously reported that calpain I knockout platelets showed 
reduced ability to mediate clot retraction (Azam et al., 2001). 
Similarly, a calpain inhibitor, MDL28170, also reduced clot re-
traction mediated by β3 integrin–expressing CHO cells (Fig. 2, 
D and E). However, the calpain substrate responsible for this effect 
of calpain was unclear. Thus, our data represent a new fi  nding 
that calpain cleavage of β3 stimulates clot retraction. This fi  nd-
ing is consistent with the data obtained in platelets. Although 
massive integrin cleavage induced by calcium ionophore or high 
concentrations of thrombin was not signifi  cantly affected in 
calpain I
−/− platelets in a previous study (possibly because of the 
involvement of Calpain II; Azam et al., 2001; Pfaff et al., 1999), 
we show in Fig. 2 F that calpain cleavage of β3 at Y
759 was con-
siderably reduced in calpain I
−/− platelets when the cleavage 
was induced by a lower concentration of thrombin (0.1 U/ml), 
which is consistent with the fi  nding that the calpain I
−/− mice 
were defective in clot retraction when clot retraction was stimu-
lated with a low concentration of thrombin (Azam et al., 2001).
To determine whether the calpain-resistant β3 mutant af-
fects integrin-dependent cell spreading, cells expressing WT or 
R760E mutant αIIbβ3 were allowed to adhere to fi  brinogen, and 
spreading kinetics of these cells were observed (Fig. 3, A and B). 
R760E mutation signifi  cantly enhanced and accelerated cell 
spreading compared with WT αIIbβ3 (P < 0.0001), indicating 
that calpain cleavage of β3 negatively regulates cell spreading. 
This result is consistent with the data that cells expressing a de-
letion mutant of β3 mimicking calpain cleavage at Y
759 (∆759 
cells) are defective in integrin-dependent cell spreading (Fig. 3 E). 
Thus, calpain cleavage of β3 negatively regulates the integrin 
outside-in signals that promote cell spreading while it stimu-
lates the integrin outside-in signaling that activates cellular 
retractile machinery.
The inhibitory effect of calpain cleavage 
of 𝗃3 on cell spreading is mediated by 
activation of RhoA-dependent 
cell retraction
The increase in clot retraction and inhibition of cell spreading by 
calpain cleavage of β3 can result either from cleavage-induced acti-
vation of cell retractile function or cleavage-induced inhibition of 
cell spreading signaling. To differentiate these two possibilities, 
we sought to inhibit the cell retractile signaling mechanisms. 
Previous studies demonstrate that stress fi  ber formation in 
cells adherent to integrin ligands requires activation of RhoA 
(Jaffe and Hall, 2003) and Rho-dependent kinases (ROCK), 
which stimulate myosin light chain phosphorylation (Amano 
et al., 1996; Kimura et al., 1996) and thus retractile function of 
the actomyosin complex (Giuliano et al., 1992). Indeed, the 
ROCK inhibitors Y-27632 or H-1152, when preincubated with 
WT β3-expressing CHO cells (Fig. 3 C) and platelets (Fig. 3 D), 
impeded clot retraction, indicating that the activation of the 
RhoA-ROCK signaling pathway is important in integrin-dependent 
cell retraction. To determine whether this pathway is responsi-
ble for calpain cleavage–dependent reversal of the direction of 
cell membrane movement, we studied the effects of ROCK inhibi-
tors on cell spreading of WT β3-expressing or calpain cleavage–
mimicking β3-expressing cells. The CHO cells expressing the 
calpain-cleaved form of β3 (∆759) were defective in spreading 
on fi  brinogen, and this defect was completely corrected by 
the ROCK inhibitors (Fig. 3 E). Spreading of CHO cells ex-
pressing WT αIIbβ3 was not signifi  cantly enhanced (P > 0.05) 
by low concentrations of ROCK inhibitors (Fig. 3, E and F). 
However, higher concentrations of either H-1152 or Y-27632 
accelerate cell spreading in WT cells (Fig. 3, G and H). Interest-
ingly, enhancement of spreading by cells expressing cleavage-
resistant integrin mutant R760E was not observed even with 
higher-dose ROCK inhibition (Fig. 3, G and H), suggesting that 
the inhibitory effect of Rho-kinase signaling on cell spreading 
is already diminished when β3 is resistant to calpain cleavage. 
These results suggest that cleavage of β3 at Y
759 caused activa-
tion of the RhoA-ROCK signaling pathway and cell retraction, 
thus preventing cell spreading.
Calpain cleavage of 𝗃3 at Y
759 induces 
RhoA activation
RhoA is activated by GTP binding and inactivated when bound 
GTP is hydrolyzed to GDP (Jaffe and Hall, 2003). The Rho bind-
ing domain (RBD) of the RhoA effector protein rhotekin specifi  -
cally binds GTP-bound RhoA and can therefore be used to 
indicate RhoA activation (Ren and Schwartz, 2000). To determine 
whether calpain cleavage of β3 stimulates RhoA activation, cells 
were allowed to spread on fi  brinogen-coated surfaces, and then 
were fi  xed, permeabilized, and incubated with fl  uorescent GST-
RBD fusion protein (GST-RBD-555). GST-RBD-555 strongly re-
acted with the WT integrin-expressing cells spreading on fi  brinogen 
(Fig. 4). GST-RBD-555 binding was specifi  c because it was 
competitively inhibited by unlabeled GST-RBD (Fig. 4 A) and by 
preincubation of cells with cell-permeable C3 transferase (Fig. 5) 
but was unaffected in the presence of 20 mM glutathione (Fig. 4 A). 
The specifi  city of GST-RBD-555 is further supported by its co-
localization with the stain of a monoclonal antibody that recognizes 
RhoA (Fig. 4 B). Thus, by using this novel in situ RhoA activation 
assay, we show that RhoA is activated after WT integrin-mediated 
cell adhesion and spreading on fi  brinogen. In contrast to WT β3, 
cells expressing the calpain-resistant β3 mutant R760E display 
reduced reactivity with GST-RBD-555, indicating that the resis-
tance to calpain cleavage by R760E mutation and increased SWITCHING THE DIRECTION OF INTEGRIN SIGNALING • FLEVARIS ET AL. 557
cell spreading in R760E cells are associated with inhibition of 
integrin-induced RhoA activation. Conversely, ∆759 cells, which 
are defective in spreading on fi  brinogen, showed robust reac-
tivity with GST-RBD-555, indicating that the calpain-cleaved 
form of β3 induces RhoA activation without requiring cell spreading. 
Collectively, these data demonstrate that cleavage of β3 at Y
759 
Figure 3.  Effects of cleavage-resistant and -mimicking 𝗃3 mutations and ROCK inhibitors on cell spreading and clot retraction. (A) Indicated cell lines were 
incubated on ﬁ  brinogen-coated chamber slides at 37°C and photographed at various times. Images at 20 min are shown. (B) Sizes of spread cells were 
quantiﬁ  ed as percentage of original sizes using Image J software. Histogram shows the mean ± SEM. (C and D) 5 μM each of ROCK inhibitors Y-27632 
and H-1152 inhibited clot retraction in platelets (D) and in CHO cells expressing WT β3 (C). (E) Spreading of WT cells and cells expressing a calpain 
cleavage–mimicking β3 mutant (∆759) on ﬁ  brinogen for 1 h. Defective spreading of ∆759 cells was corrected by 2 μM each of ROCK inhibitors H-1152 
and Y-27632. (F) Quantiﬁ  cation of cell spreading from cells in E, using image J software. Histogram shows the mean ± SEM. (G) 5 μM each of ROCK 
inhibitors H-1152 and Y-27632 enhance spreading in WT cells but not in cleavage-resistant R760E mutants at 20 min. (H) Quantiﬁ  cation of cell spreading 
from cells in G, using image J software. Histogram shows the mean ± SEM.JCB • VOLUME 179 • NUMBER 3 • 2007  558
switches on the RhoA-ROCK signaling pathway, leading to cell 
retraction and inhibition of cell spreading.
Effects of calpain cleavage–resistant or 
–mimicking mutations on c-Src binding to 𝗃3
It has been reported that a member of the Src family of protein 
kinases (SFK), c-Src, interacts with the β3 cytoplasmic domain 
and that this interaction requires the YRGT
762 sequence in the 
C terminus of β3 (Arias-Salgado et al., 2005a,b). To determine 
whether c-Src interaction with β3 is affected by the R760E muta-
tion or calpain cleavage–mimicking truncation of β3, WT and 
mutant β3, stably expressed in CHO cells, were immunoprecipi-
tated with Ab8053, an anti-β3 antibody, and precipitates were 
immunoblotted for β3-associated c-Src (Fig. 6). We found that 
Figure 4.  Calpain cleavage of 𝗃3 stimulates RhoA 
activation. (A) WT, R760E, and ∆759 cells spreading on 
ﬁ  brinogen for 1 h were ﬁ  xed and allowed to react with 
Alexa Fluor 555–labeled rhotekin (GST-RBD-555 [red]) to 
indicate RhoA activation. To estimate nonspeciﬁ  c binding, 
ﬂ  uorescent rhotekin binding was also performed in the 
presence of unlabeled rhotekin (NC) or 20 mM gluta-
thione (glut). MAb 15 (green) serves as a marker for cell 
margins and integrin β3 expression. (B) Activated RhoA, 
indicated by GST-RBD-555 (red), colocalizes with anti-
RhoA (green). Bars, 10 μm.SWITCHING THE DIRECTION OF INTEGRIN SIGNALING • FLEVARIS ET AL. 559
c-Src coimmunoprecipitated with both WT and R760E mutant 
forms of β3 but failed to interact with the cleavage-mimicking 
mutant ∆759 (Fig. 6). These data are consistent with previous 
studies (Arias-Salgado et al., 2005a,b), indicating that cleavage 
of the β3 C-terminal RGT sequence disrupts c-Src binding to β3.
Calpain cleavage of 𝗃3 at Y
759 relieves the 
inhibitory effect of c-Src on RhoA activation 
and thus promotes cell retraction
It has been shown that c-Src plays an important role in cell 
spreading (Kaplan et al., 1995) and that c-Src interaction with 
β3 is important for this function (Arias-Salgado et al., 2003; Shattil, 
2005). Therefore, we examined whether the loss of β3-associated 
c-Src function is responsible for the activation of cell retraction 
and inhibition of cell spreading induced by calpain cleavage 
at Y
759. PP2, an SFK inhibitor, abolished WT β3-mediated cell 
spreading on fi  brinogen (Fig. 7, A and D). [ID]FIG7[/ID] The inhibitory effect 
of PP2 bears striking resemblance to the defi   ciency in cell 
spreading in ∆759 cells. More importantly, the inhibitory effect 
of PP2 was reversed by ROCK inhibitors H-1152 and Y-27632, 
indicating that the RhoA-ROCK–mediated retractile signaling is 
required for the inhibitory effect of this SFK inhibitor on cell 
spreading (Fig. 7, A and D), which is similar to the requirement 
for ROCK in β3 cleavage–mediated inhibition of cell spreading. 
To exclude the possible nonspecifi  c effect of pharmacological 
inhibitors, WT β3-expressing cells were transfected with cDNA, 
encoding a dominant-negative mutant of c-Src (K295R/Y527F; 
Mukhopadhyay et al., 1995), and cotransfected with 1/6 quantity 
of GFP cDNA to indicate successful transfection. The control 
cells expressing transfected GFP exhibited normal cell spread-
ing on fi  brinogen (Fig. 7, B and E). In contrast, the cells trans-
fected with the dominant-negative c-Src showed a defect in cell 
spreading similar to that caused by PP2 (Fig. 7, B and D). This 
inhibitory effect of the dominant-negative c-Src was reversed 
when cells were cotransfected with an equal concentration of 
dominant-negative RhoA (N19-RhoA; Fig. 7, B and D; Qiu 
et al., 1995). The data obtained with cDNA transfection is thus 
consistent with the data using inhibitors of SFK and ROCK, indi-
cating that integrin-dependent cell spreading occurs independent 
of c-Src when RhoA-mediated retractile signaling is disabled. 
Because integrin-mediated c-Src activation inhibits RhoA but 
does not affect cdc42 and Rac functions (Arthur et al., 2000), 
our data indicate that c-Src promotes integrin-dependent cell 
spreading by its inhibition of RhoA-mediated retractile signals. 
Furthermore, the SFK inhibitor PP2 corrected the defective 
RhoA activation in calpain cleavage–resistant R760E cells, 
restoring RhoA activation and inhibiting the spreading of R760E 
cells (Fig. 7, C and F), which is similar to the phenotype ob-
served in ∆759 cells expressing the calpain-cleaved form of β3. 
These results indicate that without calpain cleavage of β3, 
β3-dependent c-Src activity inhibits RhoA activation and thus 
promotes cell spreading. Conversely, inhibition of SFK with PP2 
dramatically enhanced clot retraction (Fig. 7 G), further demon-
strating that SFK inhibits cell retractile machinery. Therefore, 
cleavage of β3 at Y
759 relieves the inhibitory effect of c-Src on 
RhoA activation, switches on RhoA-ROCK–dependent cell 
retraction, and thus changes the functional outcome of integrin 
signaling from cell spreading to cell retraction.
Figure 5.  Inhibition of GST-RBD binding to active RhoA by 
cell-permeable C3 transferase. Cells expressing WT αIIbβ3 
were preincubated with or without 5 μg/ml of cell-permeable 
C3 transferase and were allowed to spread on ﬁ  brinogen-
coated surfaces for 1 h. Cells were stained with GST-RBD-
555 (red) to detect active RhoA and with mAb 15 (green) 
to mark integrin surface expression. Bars, 10 μM.
Figure 6.  Coimmunoprecipitation of c-Src with WT 𝗃3 and 𝗃3 mutants. 
(A) β3 immunoprecipitates from CHO cells expressing WT, R760E mutant, 
and ∆759 mutant integrins were probed on Western blots with antibodies 
against β3 (mAb 15) or c-Src. c-Src binding to the integrin cytoplasmic domain 
is abolished in the calpain cleavage–mimicking mutant ∆759 but not in the 
calpain cleavage–resistant mutant R760E. (B) Lysates were also immuno-
blotted with antibody to c-Src.JCB • VOLUME 179 • NUMBER 3 • 2007  560
Figure 7.  The effect of calpain cleavage of 𝗃3 on c-Src–dependent inhibition of RhoA-mediated cell retraction. (A) WT cells incubated with or without 
10 μM PP2 or PP2 plus 4 μM of ROCK inhibitors H-1152 or Y-27632 were allowed to spread on ﬁ  brinogen for 1 h. Inhibition of cell spreading by PP2 is 
reversed by ROCK inhibitors. Bar, 10 μm. (B) Spreading of WT cells transfected with GFP alone, a dominant-negative c-Src (DN c-Src) plus GFP, N19-RhoA 
plus GFP, or N19-RhoA and dominant-negative c-Src plus GFP. Note that N19-RhoA reversed the inhibitory effect of dominant-negative c-Src. (C) R760E 
cells are allowed to adhere to ﬁ  brinogen in the presence of PP2 or vehicle control DMSO and are stained with GST-RBD-555 (red) and mAb 15 (green). 
Defective RhoA activation in R760E cells is corrected by PP2. Bars, 10 μM. (D) Quantitation of cell sizes in A using Image J (mean ± SEM from four random 
ﬁ  elds). (E) Quantitation of cell sizes in B using Image J (mean ± SEM from three experiments). (F) Stain of GST-RBD-555 in cells from C was quantiﬁ  ed using 
LSM 5 software (mean ± SEM from three experiments). (G) 10 μM of SFK inhibitor PP2 accelerates clot retraction in platelets.SWITCHING THE DIRECTION OF INTEGRIN SIGNALING • FLEVARIS ET AL. 561
Cleavage of 𝗃3 at Y
759 diminishes c-Src– 
dependent cell spreading by dissociating 
c-Src from 𝗃3 but not by inhibiting overall 
c-Src activation
Previous studies suggested that activity of c-Src associated with 
β3 is increased compared with that of c-Src that is not associ-
ated with β3 (Arias-Salgado et al., 2005a). To investigate the 
possibility that cleavage of β3 at Y
759 regulates integrin-dependent 
overall c-Src activation in adherent cells, we measured the 
amount of active c-Src in CHO cells expressing WT and calpain 
cleavage–resistant (R760E) and –mimicking (∆759) mutants of β3. 
All three cell lines were similarly capable of inducing con-
siderable c-Src phosphorylation at Y
416 (an indicator of c-Src 
activation) when allowed to adhere and spread onto fi  brinogen-
coated surfaces (Fig. 8 A), suggesting that deletion of the c-Src 
binding site in β3 did not affect the overall integrin-mediated 
c-Src activation. Furthermore, if c-Src activity alone was suffi  -
cient to mediate the inhibition of RhoA, constitutively active 
c-Src would be able to induce integrin-mediated cell spreading. 
Thus, ∆759 cells were transfected with cDNA encoding a con-
stitutively active mutant of c-Src (E378G) and cotransfected with 
1/6 quantity of GFP cDNA to indicate successful transfection. 
Increased levels of total c-Src and expression of constitutively 
active c-Src (Y
416 phosphorylated) in E378G c-Src–transfected 
∆759 cells in suspension were verifi  ed by Western blot (Fig. 8 B). 
The E378G c-Src–transfected ∆759 cells are not different from the 
GFP-expressing control ∆759 cells in that both spread poorly 
on fi  brinogen (Fig. 8, C and D). These data suggest that the 
inhibitory effect of β3 cleavage on cell spreading is not because 
of its effect on overall c-Src activation but is associated with 
dissociation of c-Src (and therefore c-Src activity) from the 
β3 cytoplasmic domain. Thus, only the β3-associated c-Src activity 
is responsible for mediating RhoA inhibition and promoting cell 
spreading. Collectively, our results strongly suggest that cleav-
age of β3 at Y
759 dissociates c-Src from the β3 C-terminal do-
main and thus relieves the inhibitory effect of β3-associated 
c-Src on RhoA activation, stimulating the RhoA-ROCK retractile 
signals, which switches the functional outcome of integrin signal-
ing from mediating cell spreading to promoting cell retraction.
Discussion
In this study, we have discovered that β3 cleavage by calpain 
serves as a molecular switch that changes the outcome of integ-
rin outside-in signaling from mediating cell spreading to pro-
moting cell retraction. The switch in the outcome of integrin 
signaling from cell spreading to retraction is mediated by β3 
cleavage–dependent activation of the RhoA retractile signaling 
pathway, and β3 cleavage–dependent activation of the RhoA 
signaling pathway is mediated by cleavage-dependent relief of 
Figure 8.  The effect of c-Src activation on the integrin-cleavage–dependent inhibition of cell spreading. (A) WT, R760E, and ∆759 cells were either in 
suspension or allowed to spread on ﬁ  brinogen for 30 min, and then solubilized and analyzed by Western blot with antibodies speciﬁ  c for c-Src or for 
Src phosphorylated at Y
416 as an indicator of Src activation. Note that c-Src activation is similar in all three cell lines. (B) ∆759 cells were transfected with 
either GFP or GFP plus a constitutively active mutant of c-Src, E378G. Nonadherent transfected cells were solubilized and immunoblotted with antibodies 
against total c-Src, Y
416-phosphorylated c-Src, and β3 (Ab8053, to verify equal loading). (C) ∆759 cells were transfected with GFP alone or GFP plus a 
constitutively active mutant of c-Src, E378G. The transfected cells were allowed to spread on ﬁ  brinogen-coated surfaces. Note that active c-Src cannot reverse 
the spreading defect in ∆759 cells. (D) Quantitation of cell sizes in C using Image J software (mean ± SEM from three experiments).JCB • VOLUME 179 • NUMBER 3 • 2007  562
the inhibitory effects of β3-associated c-Src on the RhoA signal-
ing pathway. Thus, our study also reveals that the requirement 
of SFK in integrin-dependent cell spreading is caused by its in-
hibition of the RhoA-dependent retractile function of the cell. 
These new fi  ndings represent major conceptual advances in our 
understanding of how integrin signaling controls and regulates 
the direction of cell membrane movement.
The data supporting our conclusions in this study are 
mainly obtained using the reconstituted integrin signaling model 
in CHO cells expressing WT and calpain cleavage–resistant 
or –mimicking mutants of β3. Integrins play critical roles in all 
mammalian cells that adhere to extracellular matrix. Although 
different cell types express different members of the integrin 
family, integrin signaling, particularly outside-in signaling, is 
generally conserved in adherent cells, including CHO cells. 
In the past 20 yr, many important fi  ndings in β3 integrin function 
and signaling have been discovered using the CHO cell model 
expressing the WT and mutant β3 integrins, including the fi  nd-
ing of the important role of talin in integrin activation (O’Toole 
et al., 1990; Calderwood et al., 1999; Tadokoro et al., 2003; 
Xi et al., 2003). Furthermore, the results obtained in CHO cells 
have been consistently verifi  ed in native β3-expressing cells, 
such as platelets (Li et al., 2001, 2003a, 2006; Tadokoro et al., 
2003; Zou et al., 2007), indicating the validity of the CHO cell 
model. Importantly, the data obtained in CHO cell models in 
this study are consistent with the role of calpain I in clot retrac-
tion and in β3 cleavage as indicated in experiments using human 
and mouse platelets. Nevertheless, it is recognized that CHO 
cells are not totally identical to native β3-expressing cells such 
as platelets, and thus the results obtained with the CHO cell 
model will need to be further verifi  ed in platelets and other 
β3-expressing cells in the future.
We have previously shown that the cytoplasmic domain of 
β3 is a calpain substrate and that the cleavage occurs mainly at 
Y
759, removing the C-terminal RGT sequence (Du et al., 1995; 
Xi et al., 2003). However, although calpain is activated after cal-
cium elevation is induced by ligand binding to the integrin, very 
little cleavage of β3 occurs early during cell spreading because 
of the protection of integrin from calpain cleavage by tyrosine 
phosphorylation of the β3 cytoplasmic domain, especially at the 
periphery of a cell (Xi et al., 2006). In contrast, at a later time 
during cell spreading when Y
759 of β3 becomes dephosphory-
lated, substantial β3 cleavage occurs (Xi et al., 2006). Also, 
  calpain cleavage of β3 is readily detectable both during clot 
retraction in platelets and in the β3-expressing CHO cells. 
The kinetics of integrin cleavage are consistent with our data, 
indicating a role for calpain in the transition between cell spreading 
and cell retraction in both CHO cells and in platelets. In fact, the 
data obtained with cells expressing the calpain-resistant and cal-
pain cleavage–mimicking mutants clearly reveal that cleavage 
of β3 at Y
759 generates the change in integrin signaling from 
mediating cell spreading to promoting cell retraction. Thus, we 
have discovered a calpain-dependent molecular switch that is 
regulated temporally and topographically by tyrosine phosphor-
ylation of β3 and that controls the direction of membrane and 
cytoskeleton movement induced by integrin outside-in signaling. 
It is important to note that the cleavage-mimicking mutant of 
β3 creates an experimental condition where 100% of β3 cyto-
plasmic domain is cleaved at Y
759, which serves to clearly reveal 
the cleavage-induced changes in functional outcome. In plate-
lets, >22% of β3 is cleaved at Y
759 within an hour after platelet 
activation (Xi et al., 2003), which coincides with the occurrence 
of marked clot retraction. However, in more delicate situations, 
such as during cell spreading and migration, local and dynamic 
calpain activation signals are likely to cause localized cleavage 
of a small percentage of β3 molecules and thus dynamically 
control the local movement of membranes and cytoskeleton.
The β3 cleavage–mediated inhibition of cell spreading 
and promotion of cell retraction is not caused by its inhibition 
of cell spreading mechanisms but is mediated by the integrin 
cleavage-dependent activation of the RhoA retractile signaling 
pathway. Previous studies suggest that Rac and cdc42 play im-
portant roles in mediating cell spreading (fi  lopodia and lamelli-
podia formation) and that RhoA is increasingly activated in 
spread cells (Hall, 2005). RhoA activates ROCK, which phos-
phorylates and inactivates myosin light chain phosphatase, and 
enhances myosin light chain phosphorylation and retractile 
function of the actomyosin complex (Giuliano et al., 1992; Amano 
et al., 1996; Kimura et al., 1996), inducing cell retraction. 
Cleavage of β3 at Y
759 inhibits integrin-mediated cell spreading 
(Fig. 3; Xi et al., 2003). If the inhibitory effects of β3 cleavage 
on cell spreading should result from its inhibition of Rac- and 
cdc42-mediated cell spreading signaling, this inhibitory effect 
should not be corrected by inhibition of RhoA pathway. There-
fore, our data that β3 cleavage–dependent inhibition of cell 
spreading is corrected by ROCK inhibitors indicate that calpain 
cleavage of β3 activates RhoA-dependent cell retraction, which 
subsequently inhibits the opposite movement of cell membrane 
resulting in inhibition of cell spreading.
Previous studies indicate that members of SFK are re-
quired for integrin-mediated signaling that leads to cell spread-
ing (Shattil, 2005). The mechanism responsible for this role of 
SFK is not clear but is believed to be an early step in cell spread-
ing signaling. However, we show that the inhibitory effect of 
an SFK inhibitor and a dominant-negative c-Src mutant on 
β3-mediated cell spreading is reversed by inhibition of the RhoA 
signaling pathway, indicating that cell spreading is independent 
of c-Src when RhoA signaling is abrogated. These data there-
fore provide the fi  rst direct evidence that the role of SFK in 
promoting integrin-dependent cell spreading is not that it is 
required for cdc42- and Rac-dependent cell spreading signaling, 
but rather is its inhibition of RhoA-dependent retractile signaling 
and thus cell retraction, which confi  nes the outward movement of 
the cell membrane and cytoskeleton. Our data are consistent 
with the previous studies, which show that SFK inhibits RhoA 
activity but has no effect on the activity of cdc42 and Rac (Arthur 
et al., 2000). Our data are also consistent with the fi  nding that 
RhoA inactivation by p190RhoGAP promotes membrane pro-
trusion and polarity (Arthur and Burridge, 2001). More impor-
tantly, we show that cleavage of β3 at Y
759 abolishes c-Src 
binding to β3 but does not signifi  cantly affect overall c-Src acti-
vation in cells spread on fi  brinogen, and that the RhoA-dependent 
inhibition of cell spreading by β3 cleavage at Y
759 is not reversed 
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that whereas overall intracellular c-Src activation during cell 
adhesion does not require c-Src association with β3, active c-Src 
molecules dissociated from β3 are not capable of inhibiting 
the RhoA signaling pathway and promoting cell spreading on 
β3 ligands, possibly because of the lack of β3 scaffold. However, 
the calpain cleavage–resistant mutation in β3 inhibits RhoA ac-
tivation in a Src-dependent manner. Thus, our results suggest that 
only the β3-associated c-Src is responsible for the inhibition of 
the RhoA pathway and facilitation of cell spreading. Conversely, 
our results suggest that calpain cleavage of β3, which abolishes 
Src binding to β3 (Fig. 6; Arias-Salgado et al., 2005b), relieves 
the inhibitory effects of β3-associated c-Src on the RhoA path-
way, activates RhoA, and thus switches the outcome of integrin 
signaling from cell spreading to retraction.
Interestingly, β3 cleavage–dependent relief of c-Src–
mediated RhoA inhibition and activation of RhoA-dependent 
cell retraction is associated with the cleavage of only a fraction 
of β3 molecules (Fig. 2; Xi et al., 2003) and cannot be prevented 
by the presence of uncleaved β3 molecules in the same cell. 
This apparently dominant effect of β3 cleavage suggests that 
c-Src activity at one location in a cell does not cross-inhibit RhoA 
activation induced by calpain cleavage of β3 at a different loca-
tion and is consistent with the knowledge that spreading (such as 
fi  lopodia and lamellipodia) and retraction can occur simultane-
ously at different locations within a cell (such as during cell 
migration). The requirement of c-Src association with β3 for the 
c-Src–mediated RhoA inhibition provides a mechanism for the 
localized role of c-Src in promoting cell spreading. Further 
studies are required to understand how β3-associated c-Src activity 
locally regulates RhoA and whether additional mechanisms are 
needed for RhoA activation when β3 cleavage by calpain re-
lieves the inhibitory effect of β3-associated c-Src.
Based on data from this and other studies, we propose a 
new model of integrin signaling that incorporates a phosphory-
lation- and protease-mediated mechanism regulating integrin-
mediated cell membrane movements. In this model (Fig. 9), 
initial integrin signaling activates protein tyrosine kinases, 
which induce phosphorylation of the cytoplasmic domain of β3 
(Law et al., 1996, 1999), and elevates intracellular calcium 
levels, which activate calpain (Fox et al., 1993). Tyrosine phos-
phorylation at Y
759 of β3 in the early phase of cell spreading 
protects the c-Src binding site in the C-terminal domain of β3 
from calpain cleavage (Xi et al., 2006). The interaction of c-Src 
with β3 promotes activation of β3-associated c-Src by a Csk- 
(Obergfell et al., 2002) and protein tyrosine phosphatase IB–
dependent mechanism (Arias-Salgado et al., 2005a) and/or allows 
c-Src–dependent signaling in the vicinity of the β3 C terminus, 
which facilitates cell spreading by inhibiting RhoA-dependent 
cell retraction. In spread cells, Y
759 of β3 becomes dephos-
phorylated (Xi et al., 2006), allowing β3 cleavage by activated 
calpain, which removes the C-terminal RGT sequence of β3 im-
portant in c-Src binding. Integrin cleavage by calpain thus re-
lieves the local inhibitory effect of β3-associated c-Src on the 
RhoA-ROCK signaling pathway and locally activates RhoA-
dependent cell retractile signals (Xi et al., 2003; Arias-Salgado 
et al., 2005b). Thus, calpain cleavage of β3 switches the direction 
of integrin outside-in signaling from mediating spreading to 
promoting cell retraction.
Figure 9.  A new calpain-dependent switch 
that controls cell spreading and retraction. 
This schematic illustrates the calpain-dependent 
switch that controls the direction of integrin 
signaling. In this model, ligand binding to 
integrins induces not only Rac- and cdc42-
dependent cell spreading signals, but also 
phosphorylation of the cytoplasmic domain of 
β3 and elevation of intracellular calcium levels 
that activate calpain. Tyrosine phosphorylation 
at Y
759 of β3 protects the c-Src binding site in the 
C-terminal domain of β3 from calpain cleavage. 
The β3-associated c-Src facilitates cell spreading 
by inhibiting RhoA-dependent cell retraction 
signals. In spread cells, Y
759 of β3 becomes 
dephosphorylated, allowing β3 cleavage by 
calpain. Removal of the c-Src binding site in β3 
by calpain relieves the local inhibitory effect of 
c-Src on the RhoA-ROCK signaling pathway, 
activates RhoA-dependent cell retraction, and 
thus switches the outcome of local integrin sig-
naling from mediating cell spreading to retraction. 
However, the possible involvement of additional 
pathways is not totally excluded.JCB • VOLUME 179 • NUMBER 3 • 2007  564
Materials and methods
Reagents
Plasma containing 0.38% sodium citrate and 40 μg/ml aprotinin (Sigma-
Aldrich) was depleted of ﬁ  bronectin as previously reported in Chen et al. 
(1994). Ab762 and Ab759 were previously described in Du et al. (1995) 
and Xi et al. (2003). mAb 15, D57, and Ab8053 were provided by 
M. Ginsberg (University of California, San Diego, La Jolla, CA; O’Toole et al., 
1990). Phosphospeciﬁ  c anti-Src Y
416 antibody was obtained from Cell Sig-
naling; anti-RhoA and cell permeable C3 transferase were obtained from 
Cytoskeleton, Inc.; Sudan black was obtained from Sigma-Aldrich; Alexa 
Fluor 594–conjugated goat anti–rabbit IgG and Alexa Fluor 488–
conjugated goat anti–mouse IgG were obtained from Invitrogen; anti–v-Src 
monoclonal antibody, SFK inhibitor PP2, ROCK inhibitors H-1152 and 
Y-27632, and calpain inhibitor MDL 28170 were obtained from Calbio-
chem; and an anti–c-Src polyclonal antibody was obtained from Santa 
Cruz Biotechnology, Inc. GST-RBD cDNA were a gift from T. Kozasa 
(University of Illinois, Chicago, IL). GST-RBD fusion protein was puriﬁ  ed as 
previously described in Ren and Schwartz (2000). Puriﬁ  ed protein was 
ﬂ  uorescently labeled with an Alexa Fluor 555 microscale protein labeling 
kit (Invitrogen).
Construction of R760E mutant
The β3 R760E mutation was performed using PCR. The forward primer has 
the sequence of A  G  A  G  C  T  T  A  A  G  G  A  C  A  C  . The reverse primers (C  T  C  A  T  T  A  A-
G  T  C  C  C  C  T  C  G  T  A  G  G  T  G  A  T  A  T  T  G  G  ) contain an XhoI digestion site, stop 
codon, and the 18-nucleotide C-terminal β3 sequence coding the intended 
R760E mutation. PCR products were digested with AspI and XhoI and li-
gated into a β3 cDNA construct in a modiﬁ  ed cDM8 vector containing only 
one XhoI site at the 3′ end of the multiple cloning site. The construct was 
veriﬁ  ed by DNA sequencing.
Cell lines and transfection
CHO cells stably expressing WT human αIIbβ3 (2b3a), human glyco-
protein Ib-IX (GPIb-IX; 1b9), or both αIIbβ3 and GPIb-IX (123) were previously 
described in Gu et al. (1999) and Xi et al. (2003). CHO cells expressing 
GPIb-IX and a truncation mutant β3, mimicking calpain cleavage at Y
759, 
and complexed with WT αIIb (∆759) were also described previously in 
Gu et al. (1999) and Xi et al. (2003). DNA transfection was performed 
using Lipofectamine 2000 (Invitrogen). R760E β3 mutant cDNA was co-
transfected with WT αIIb and pcDNA 3.1/Hyg plasmid at a ratio of 5:5:1 
into 1b9 cells. Complex formation between αIIb and β3 subunits was veri-
ﬁ  ed by ﬂ  ow cytometry using antibody D57 against αIIbβ3 complex. Stable 
R760E mutant cell lines were obtained by antibiotic selection and re-
peated cell sorting using D57 as previously described (Gu et al., 1999). 
To ensure comparable expression, R760E and ∆759 cells were sorted 
using the expression level of the stable WT αIIbβ3-expressing (123) cells 
as a gate (Gu et al., 1999; Xi et al., 2003). For transient transfections, 
cells stably coexpressing WT αIIbβ3 were transfected with either 2 μg 
GFP, 2 μg GFP plus 12 μg of dominant-negative c-Src (Mukhopadhyay 
et al., 1995), 2 μg GFP plus 12 μg of dominant-negative N19-RhoA 
(Qiu et al., 1995), or 2 μg GFP plus 12 μg of both dominant-negative 
c-Src and N19-RhoA, using Lipofectamine 2000. In some experiments, 
cells were transiently transfected with either 2 μg GFP or 2 μg GFP plus 
12 μg of constitutively active c-Src (E378G). Cells were analyzed 24 h 
after transfection.
Calpain cleavage of 𝗃3 in CHO cells and mouse platelets
10
7 CHO cells were directly solubilized in buffer containing 2% Triton 
X-100, 0.15 M NaCl, 1 mM CaCl2, and 0.02 M Tris, pH 7.4, in the pres-
ence or absence of 10 mM EDTA. Cell lysates were incubated for 40 min 
at 37°C with or without 1 μg of puriﬁ  ed μ-calpain. SDS-PAGE sample buf-
fer containing 10 mM EDTA, 1 mM PMSF, and 0.2 mM E64 was added to 
stop reactions. For experiments using mice, 6–8-wk-old mice of either sex 
were anesthetized by intraperitoneal injection of pentobarbital and blood 
was drawn from the inferior vena cava. Blood from 5–6 (calpain I
+/+ and 
calpain I
−/−; Azam et al., 2001) mice was pooled or platelets were 
isolated by differential centrifugation as described in Li et al. (2003b). 
3 × 10
8/ml washed platelets were resuspended in modiﬁ  ed Tyrode’s buffer 
(Du et al., 1991) and incubated at 22°C for 2 h before use. Platelets were 
stimulated with 0.1 U/ml thrombin in a platelet aggregometer at 37° for 
7 min, and then solubilized in SDS-PAGE sample buffer. All samples were 
analyzed by SDS-PAGE using 4–15% gradient gels and were immuno  blotted 
using various antibodies. Enhanced chemiluminescence (GE Healthcare) 
was used for visualization of antibody reactions.
Immunoﬂ  uorescence and confocal microscopy
Chamber slides (Lab-Tek; Nunc) were precoated with 10 μg/ml ﬁ  brinogen 
and blocked with 5% BSA in PBS. 50 μl CHO cells (expressing WT or mu-
tant integrins; 5 × 10
5/ml) in Tyrode’s buffer was added to the wells and 
incubated at 37°C for 1 h. After washing, cells were ﬁ  xed with 4% para-
formaldehyde and permeabilized with 0.1% Triton X-100, 0.1 M Tris, 10 mM 
EGTA, 0.15 M NaCl, 5 mM MgCl2, 1 mM PMSF, 0.1 mM E64, and 
1% BSA (permeabilization buffer, pH 7.5). Samples were blocked with 
5% BSA, incubated with 10 μg/ml mAb 15 and 0.5 μg/ml of puriﬁ  ed 
Ab759, and, after washing, stained with ﬂ  uorescently labeled secondary 
antibodies. To detect RhoA activation, cells were ﬁ  xed in 4% paraformal-
dehyde in PBS with 10 mM MgCl2 and incubated with 0.7 μg/ml mAb 15 
and Alexa Fluor 555–labeled GST-RBD in permeabilization buffer containing 
10 mM MgCl2. After further staining with Alexa Fluor 488–conjugated 
goat anti–mouse IgG and washes, the antibody and GST-RBD staining 
were detected using a confocal microscope (Carl Zeiss MicroImaging, Inc.). 
In some experiments, cells were also preincubated with or without 5 μg/ml 
of cell-permeable C3 transferase to inhibit RhoA, according to the manu-
facturer’s instructions, and then stained with GST-RBD-555. Surface area in 
spreading cells was estimated by measuring total pixel number per cell in 
digitally recorded images using Image J software (National Institutes of 
Health). Quantitation of 555-nm ﬂ  uorescence in R760E cells was deter-
mined by using the area tool in LSM 5 software (Carl Zeiss MicroImaging, 
Inc.) and expressed as total pixel number. Statistical signiﬁ  cance was deter-
mined using a t test.
Clot retraction
400 μl of indicated CHO cell lines (4 × 10
6/ml), in complete DME in the 
presence or absence of 5 μM ROCK inhibitors H-1152 or Y-27632 or cal-
pain inhibitor MDL 28170, was mixed with 100 μl of plasma, 2 U/ml 
thrombin, and 5 mM CaCl2 in a partially Sigmacote-treated glass cuvette 
(Chrono-Log). For platelet samples, citrated platelet-rich plasma was mixed 
with 0.2 U/ml thrombin. The clots were allowed to retract at 37°C and 
were photographed at various times. The two-dimensional sizes of retracted 
clots on photographs were quantiﬁ  ed using Image J software and were ex-
pressed as clot size. Statistical signiﬁ  cance was determined using a t test.
Confocal microscopy analysis of clot sections
Clots were ﬁ  xed with 4% paraformaldehyde, embedded in 50% Tissue-Tek 
OCT compound (Sakura Finetek), placed in 25 × 20 × 5-mm Tissue-Tek 
Cryomolds (Sakura Finetek), and snap frozen in liquid nitrogen. Frozen 
sections were made using a cryostat microtome (Microm HM 505 E; Carl 
Zeiss MicroImaging, Inc.). Slides were then washed and quenched with 
5% Sudan black (wt/vol) in 70% ethanol. Sections were permeabilized 
with 0.1% Triton X-100, 0.1 M Tris, 10 mM EGTA, 0.15 M NaCl, 5 mM 
MgCl2, 1 mM PMSF, 0.1 mM E64, and 1% BSA, pH 7.5 (permeabilization 
buffer), blocked with 5% BSA, and immunolabeled with 10 μg/ml mAb 15 
and 0.5 μg/ml of puriﬁ  ed Ab 759. After washing, cells were stained with 
Alexa Fluor 594–conjugated anti–rabbit IgG and 488–conjugated anti–
mouse IgG. Data was collected using a confocal microscope.
Spreading assays
CHO cells expressing WT, R760E mutant, and ∆759 mutant integrins 
(100 μl/well, 1.5 × 10
5/ml) in complete DME were incubated in ﬁ  brinogen-
coated chamber slides at 37°C for 20, 40, and 60 min. At each time, cells 
were immediately rinsed and ﬁ  xed with 4% paraformaldehyde. For assays 
using PP2 and ROCK inhibitors, cells were preincubated at 22°C for 
30 min with or without 10 μM PP2 and/or 4 μM H-1152 or Y-27632. 
Cells were allowed to spread for 1 h at 37°C, rinsed, and ﬁ  xed with 4% 
paraformaldehyde. Images were captured using a microscope (DM IRB; 
Leica). The size of the cells from four random ﬁ  elds for each time and cell 
line was determined using Image J software. Relative increase in cell size 
was calculated by dividing the mean size of spread cells by the mean size 
of suspended cells from each cell line. Statistical signiﬁ  cance was deter-
mined using a t test.
Immunoprecipitation
Cells were lysed in lysis buffer containing 1% NP-40, 150 mM NaCl, 50 mM 
Tris, pH 7.4, 1 mM sodium orthovanadate, 1 mM NaF, and Complete pro-
tease inhibitor mixture (Roche Molecular Biochemicals). Lysates were incu-
bated with either rabbit anti-β3 or an equal amount of rabbit IgG and 
subsequently with protein A–Sepharose (GE Healthcare). Beads were 
washed four times with lysis buffer, analyzed by SDS-PAGE using 4–15% 
gradient gels, and immunoblotted with mAb 15 for β3 and monoclonal 
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Immunoblot analysis of c-Src activation in cells adherent on 
ﬁ  brinogen-coated surfaces
10-cm polystyrene dishes (Fisher Scientiﬁ  c) were coated with 10 μg/ml 
ﬁ  brinogen and blocked with 5% BSA in PBS. Equal suspensions containing 
5 × 10
6 CHO cells stably expressing WT, R760E mutant, or ∆759 mutant 
integrins in modiﬁ   ed Tyrode’s buffer were either kept in suspension or 
added to the dishes and incubated at 37°C for 30 min. Plates were rinsed 
three times with PBS and cells were subsequently lysed with the buffer con-
taining 1% NP-40, 150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM sodium 
orthovanadate, 1 mM NaF, and Complete protease inhibitor mixture. Lysates 
were analyzed by SDS-PAGE using 4–15% gradient gels, and then immuno-
blotted with anti–phospho-Src Y
416 and anti–c-Src.
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